metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)
versus Standard of Care (SoC)
	atezolizumab plus bevacizumab
	IMbrave050, 2023 Lancet 2023; 402:1835-1847-. NCT04102098	RCT	mHCC - (neo)adjuvant (NA)	atezolizumab plus bevacizumab	active surveillance	adult patients with high-risk surgically resected or ablated hepatocellular carcinoma	334 / 334	NA	conclusif	demonstrated 28 % decrease in RFS/DFS (PE)
mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)
versus sorafenib
	atezolizumab plus bevacizumab
	IMbrave-150, 2020 N. Engl. J. Med. 2020; 382:1894-1905 The Lancet Oncology J Hepatol 2022; 76:862-873-. NCT03434379	RCT	mHCC - 1st line (L1)	atezolizumab-bevacizumab	sorafenib	patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment	336 / 165	some concern	conclusif	demonstrated 42 % decrease in deaths (OS) (PE) demonstrated 41 % decrease in progression or deaths (PFS) (PE) demonstrated 1.8-fold increase in objective responses (ORR) (PE)
	atezolizumab plus cabozantinib
	COSMIC-312, 2023 Future Oncol 2020 Jul;16(21):1525-1536. Annals of Oncology Lancet Gastroenterol Hepatol 2024; 9:310-322-. Lancet Oncol 2022; 23:995-1008-. NCT03755791	RCT	mHCC - 1st line (L1)	cabozantinib plus atezolizumab	sorafenib	Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy	432 / 217	NA	trade-off	inconclusive 2 % decrease in deaths (OS) (PE) demonstrated 37 % decrease in progression or deaths (PFS) (PE)